Studies Show Favorable Results For PARP Inhibitors in the Treatment of Advanced Ovarian Cancer

Dr. Rachel Grisham MSK ovarian cancer section head discussed clinical trials investigating PARP inhibitors for ovarian cancer patients. The event was a round table discussion and interview for Targeted Oncology.…

Continue Reading Studies Show Favorable Results For PARP Inhibitors in the Treatment of Advanced Ovarian Cancer
6 Myths About Ovarian Cancer Debunked
https://pixabay.com/en/magnifier-glass-magnifying-glass-1714172/

6 Myths About Ovarian Cancer Debunked

Misconceptions exist about many rare diseases. In fact, the efforts of many advocates are focused on education and dispelling these myths. Recently, an article in the Hindustan Times did just…

Continue Reading 6 Myths About Ovarian Cancer Debunked

Antibody Drug Conjugates Are Being Investigated for the Treatment of Platinum-Resistant Ovarian Cancer

Targeted Oncology recently published a report citing a promising class of drugs to treat recurrent platinum-resistant ovarian cancer (PROC), often associated with a poor prognosis. PROC eventually occurs to a…

Continue Reading Antibody Drug Conjugates Are Being Investigated for the Treatment of Platinum-Resistant Ovarian Cancer
DPX Delivery Platform Could Improve Care For Many Rare Cancers
source: pixabay.com

DPX Delivery Platform Could Improve Care For Many Rare Cancers

IMV Inc. recently presented two posters at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics showcasing their DPX delivery platform's immunotherapeutic capabilities. IMV Inc. IMV Inc. is…

Continue Reading DPX Delivery Platform Could Improve Care For Many Rare Cancers
Nemvaleukin Alfa + Pembrolizumab Earn Fast Track Designation for Ovarian Cancer
source: pixabay.com

Nemvaleukin Alfa + Pembrolizumab Earn Fast Track Designation for Ovarian Cancer

Sometimes, treatments used in conjunction with each other can confer benefits for patients. According to the Cancer Network, for example, treating platinum-resistant ovarian cancer using nemvaleukin alfa and pembrolizumab (Keytruda)…

Continue Reading Nemvaleukin Alfa + Pembrolizumab Earn Fast Track Designation for Ovarian Cancer

China Conditionally Approves Pamiparib for Those with Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

BeiGene has just announced that China has given conditional approval to Pamiparib, a PARP inhibitor used as a therapy for BRCA associated ovarian cancer, fallopian tube cancer, and primary peritoneal…

Continue Reading China Conditionally Approves Pamiparib for Those with Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer